{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:55:18Z","timestamp":1787993718644,"version":"build-2784847793"},"reference-count":48,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["li.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Laboratory Investigation"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.labinv.2025.104240","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T06:39:55Z","timestamp":1757918395000},"page":"104240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Analysis of Human Epidermal Growth Factor Receptor 2 (HER2) Heterogeneity at the Protein and Gene Levels in Endometrial Cancer: Refining HER2 Reporting and HER2-Directed Therapies"],"prefix":"10.1016","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7988-9442","authenticated-orcid":false,"given":"Ekaterina","family":"Menshikova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Deeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Genega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztina","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6125-5865","authenticated-orcid":false,"given":"Gulisa","family":"Turashvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.labinv.2025.104240_bib1","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1097\/PGP.0000000000000491","article-title":"High-grade endometrial carcinomas: morphologic and immunohistochemical features, diagnostic challenges and recommendations","volume":"38","author":"Murali","year":"2019","journal-title":"Int J Gynecol Pathol"},{"issue":"4","key":"10.1016\/j.labinv.2025.104240_bib2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/PGP.0000000000000243","article-title":"TP53 Mutational spectrum in endometrioid and serous endometrial cancers","volume":"35","author":"Schultheis","year":"2016","journal-title":"Int J Gynecol Pathol"},{"issue":"3","key":"10.1016\/j.labinv.2025.104240_bib3","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/cjp2.18","article-title":"In-depth molecular profiling of the biphasic components of uterine carcinosarcomas","volume":"1","author":"McConechy","year":"2015","journal-title":"J Pathol Clin Res"},{"issue":"2","key":"10.1016\/j.labinv.2025.104240_bib4","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/path.4947","article-title":"The genetic landscape of endometrial clear cell carcinomas","volume":"243","author":"DeLair","year":"2017","journal-title":"J Pathol"},{"issue":"2","key":"10.1016\/j.labinv.2025.104240_bib5","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/PGP.0000000000000674","article-title":"Equivalent survival of p53 mutated endometrial endometrioid carcinoma grade 3 and endometrial serous carcinoma","volume":"40","author":"Brett","year":"2021","journal-title":"Int J Gynecol Pathol"},{"issue":"1","key":"10.1016\/j.labinv.2025.104240_bib6","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41379-019-0358-x","article-title":"HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy","volume":"33","author":"Rottmann","year":"2020","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.labinv.2025.104240_bib7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3390\/cancers13010044","article-title":"HER2 status in high-risk endometrial cancers (PORTEC-3): relationship with histotype, molecular classification, and clinical outcomes","volume":"13","author":"Vermij","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.labinv.2025.104240_bib8","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00428-021-03017-5","article-title":"Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy","volume":"478","author":"Yoshida","year":"2021","journal-title":"Virchows Arch"},{"issue":"2","key":"10.1016\/j.labinv.2025.104240_bib9","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/PGP.0000000000000783","article-title":"HER2 expression in endometrial cancers diagnosed as clear cell carcinoma","volume":"41","author":"Cagaanan","year":"2022","journal-title":"Int J Gynecol Pathol"},{"issue":"7","key":"10.1016\/j.labinv.2025.104240_bib10","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/s41379-021-00997-2","article-title":"Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas","volume":"35","author":"Ross","year":"2022","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.labinv.2025.104240_bib11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.labinv.2025.104240_bib12","first-page":"8","article-title":"The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma","volume":"55","author":"Karen","year":"2022","journal-title":"Pathology"},{"issue":"8","key":"10.1016\/j.labinv.2025.104240_bib13","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1097\/IGC.0000000000001050","article-title":"Clear cell carcinoma of the endometrium: evaluation of prognostic parameters in a multi-institutional cohort of 165 cases","volume":"27","author":"Abdulfatah","year":"2017","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"10.1016\/j.labinv.2025.104240_bib14","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/annonc\/mdw161","article-title":"Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma","volume":"27","author":"Matsuo","year":"2016","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.labinv.2025.104240_bib15","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.ejso.2010.09.010","article-title":"Prognostic factors in stages II\/III\/IV and stages III\/IV endometrioid and serous adenocarcinoma of the endometrium","volume":"36","author":"Mhawech-Fauceglia","year":"2010","journal-title":"Eur J Surg Oncol"},{"issue":"11","key":"10.1016\/j.labinv.2025.104240_bib16","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.annonc.2023.08.005","article-title":"HER2-low expression in patients with advanced or metastatic solid tumors","volume":"34","author":"Uzunparmak","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.labinv.2025.104240_bib17","article-title":"Antibody-drug conjugates in gynecologic cancer","volume":"43","author":"Karpel","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"16","key":"10.1016\/j.labinv.2025.104240_bib18","article-title":"Safety and efficacy of DB-1303 in patients with advanced\/metastatic solid tumors: a multicenter, open-label, first-in-human, phase 1\/2a study","volume":"41","author":"Kathleen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.labinv.2025.104240_bib19","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1200\/JCO.2005.03.4827","article-title":"HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients","volume":"24","author":"Morrison","year":"2006","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.labinv.2025.104240_bib20","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","article-title":"Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2\/Neu (NCT01367002): updated overall survival analysis","volume":"26","author":"Fader","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.labinv.2025.104240_bib21","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.labinv.2025.104240_bib22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"9742","key":"10.1016\/j.labinv.2025.104240_bib23","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.labinv.2025.104240_bib24","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/PAS.0000000000001870","article-title":"HER2 Overexpression and amplification in uterine carcinosarcomas with serous morphology","volume":"46","author":"Jenkins","year":"2022","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.labinv.2025.104240_bib25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/10668969221102529","article-title":"The prognostic effect of HER2 gene amplification in high-grade endometrial carcinomas and its correlation with protein overexpression","volume":"31","author":"Bozkurt","year":"2023","journal-title":"Int J Surg Pathol"},{"key":"10.1016\/j.labinv.2025.104240_bib26","series-title":"Uterine neoplasms, version 2.2025, NCCN clinical practice guidelines in oncology (NCCN Guidelines)","author":"Abu-Rustum","year":"2025"},{"issue":"11","key":"10.1016\/j.labinv.2025.104240_bib27","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1007\/s00535-018-1464-0","article-title":"Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer","volume":"53","author":"Wakatsuki","year":"2018","journal-title":"J Gastroenterol"},{"issue":"7","key":"10.1016\/j.labinv.2025.104240_bib28","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/PAS.0000000000002392","article-title":"Comparison of HER2 scoring systems in endometrial cancer: toward optimization of HER2-directed therapies","volume":"49","author":"Menshikova","year":"2025","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"10.1016\/j.labinv.2025.104240_bib29","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","article-title":"Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice","volume":"26","author":"Buza","year":"2013","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.labinv.2025.104240_bib30","doi-asserted-by":"crossref","first-page":"687","DOI":"10.5858\/arpa.2020-0207-RA","article-title":"HER2 Testing in endometrial serous carcinoma: time for standardized pathology practice to meet the clinical demand","volume":"145","author":"Buza","year":"2021","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"10.1016\/j.labinv.2025.104240_bib31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/PGP.0000000000000711","article-title":"HER2 testing and reporting in endometrial serous carcinoma: practical recommendations for HER2 Immunohistochemistry and fluorescent in situ hybridization. Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting","volume":"40","author":"Buza","year":"2021","journal-title":"Int J Gynecol Pathol"},{"issue":"20","key":"10.1016\/j.labinv.2025.104240_bib32","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.labinv.2025.104240_bib33","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists Guideline update","volume":"41","author":"Wolff","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.labinv.2025.104240_bib34","series-title":"Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of Gynecologic Origin","author":"Crothers","year":"2023"},{"issue":"4","key":"10.1016\/j.labinv.2025.104240_bib35","doi-asserted-by":"crossref","first-page":"611","DOI":"10.5858\/133.4.611","article-title":"Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines","volume":"133","author":"Vance","year":"2009","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"10.1016\/j.labinv.2025.104240_bib36","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"25","author":"Wolff","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.labinv.2025.104240_bib37","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1309\/AJCP0EN6AQMWETZZ","article-title":"Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition","volume":"136","author":"Bartlett","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.labinv.2025.104240_bib38","article-title":"Selection of HER2\/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma","volume":"32","author":"Pelligra","year":"2020","journal-title":"Gynecol Oncol Rep"},{"issue":"2","key":"10.1016\/j.labinv.2025.104240_bib39","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/path.6230","article-title":"Decreased HER2 expression in endometrial cancer following anti-HER2 therapy","volume":"262","author":"Chui","year":"2024","journal-title":"J Pathol"},{"issue":"12","key":"10.1016\/j.labinv.2025.104240_bib40","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/gcc.22113","article-title":"Marked heterogeneity of HER2\/NEU gene amplification in endometrial serous carcinoma","volume":"52","author":"Buza","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"issue":"11","key":"10.1016\/j.labinv.2025.104240_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100299","article-title":"HER2 genetic intratumor heterogeneity is associated with resistance to trastuzumab and trastuzumab emtansine therapy in recurrent high-grade endometrial cancer","volume":"36","author":"Shen","year":"2023","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.labinv.2025.104240_bib42","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1309\/AJCPXTZSKBRIP07W","article-title":"Frequency of HER2 heterogeneity by fluorescence in situ hybridization according to CAP expert panel recommendations: time for a new look at how to report heterogeneity","volume":"136","author":"Allison","year":"2011","journal-title":"Am J Clin Pathol"},{"issue":"11","key":"10.1016\/j.labinv.2025.104240_bib43","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.3390\/cancers16112100","article-title":"Implementation of HER2 testing in endometrial cancer, a summary of real-world initial experience in a large tertiary cancer center","volume":"16","author":"Plotkin","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.labinv.2025.104240_bib44","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/modpathol.2011.206","article-title":"\u2018Genetic heterogeneity\u2019 in HER2\/neu testing by fluorescence in situ hybridization: a study of 2,522 cases","volume":"25","author":"Chang","year":"2012","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.labinv.2025.104240_bib45","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/modpathol.2016.175","article-title":"\u2018Non-classical\u2019 HER2 FISH results in breast cancer: a multi-institutional study","volume":"30","author":"Ballard","year":"2017","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.labinv.2025.104240_bib46","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/modpathol.2013.103","article-title":"HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity","volume":"27","author":"Hanna","year":"2014","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.labinv.2025.104240_bib47","first-page":"0","article-title":"Characteristics of HER2 Gene Amplification by fluorescence in situ hybridization in endometrial serous carcinoma","volume":"146","author":"Buza","year":"2022","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"10.1016\/j.labinv.2025.104240_bib48","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/ajcp\/aqac179","article-title":"HER2 gene protein assay: a robust tool for evaluating HER2 status and intratumoral heterogeneity in endometrial cancers","volume":"159","author":"Shafi","year":"2023","journal-title":"Am J Clin Pathol"}],"container-title":["Laboratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683725001503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683725001503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T07:06:09Z","timestamp":1780729569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0023683725001503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0023683725001503"],"URL":"https:\/\/doi.org\/10.1016\/j.labinv.2025.104240","relation":{},"ISSN":["0023-6837"],"issn-type":[{"value":"0023-6837","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of Human Epidermal Growth Factor Receptor 2 (HER2) Heterogeneity at the Protein and Gene Levels in Endometrial Cancer: Refining HER2 Reporting and HER2-Directed Therapies","name":"articletitle","label":"Article Title"},{"value":"Laboratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.labinv.2025.104240","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104240"}}